Amphastar Pharmaceuticals (AMPH) Receivables - Net (2013 - 2026)

Amphastar Pharmaceuticals has reported Receivables - Net for 14 years, with the latest figure at $144.9 million in Q2 2026.

• On a quarterly basis, Receivables - Net rose 8.93% year-over-year to $144.9 million in Q2 2026; TTM through Jun 2026 was $144.9 million, a 8.93% increase from a year earlier, with the FY2025 full-year figure at $143.6 million, up 5.33% from the prior year.
• Receivables - Net was $144.9 million for Q2 2026 at Amphastar Pharmaceuticals, down from $147.8 million in the prior quarter.
• The five-year high for Receivables - Net was $147.8 million in Q1 2026, with the low at $73.2 million in Q1 2022.
• Average Receivables - Net over 5 years is $120.3 million, with a median of $132.2 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Receivables - Net retreated 6.12% in 2022, then jumped 54.33% in 2023.
• Over 5 years, Receivables - Net stood at $88.8 million in 2022, then gained by 29.43% to $114.9 million in 2023, then gained by 18.57% to $136.3 million in 2024, then rose by 5.33% to $143.6 million in 2025, then advanced by 0.9% to $144.9 million in 2026.
• The last three Receivables - Net figures came in at $144.9 million (Q2 2026), $147.8 million (Q1 2026), and $143.6 million (Q4 2025), per Business Quant data.